Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia

Not Applicable

Completed

• Conditions: Myeloid Leukemia, Chronic
• Interventions: Behavioral: Imatinib ending

• Registration Number: NCT00478985
• Lead Sponsor: University Hospital, Bordeaux

Brief Summary

The first purpose of this study is to evaluate the persistence of the complete molecular remission in patients with Chronic Myeloid Leukemia after stopping imatinib treatment (determine by Reverse Transcription real-time Polymerase Chain Reaction (RT-PCR) negative for bcr-abl transcripts). The second purpose is to determine clinicals and biologicals factors associated with the persistent complete molecular remission.

Detailed Description

Principal Objective : To evaluate the complete molecular remission persistence after stopping imatinib during six months as measured by RT-PCR negative for bcr-abl transcripts in patients with Chronic Myeloid Leukemia .

Secondary Objective :

* To determine clinicals factors associated with complete molecular remission before and after stopping imatinib in patients with Chronic Myeloid Leukemia.

* To determine the biologics factors (immunologic and molecular) associated with complete molecular remission before and after stopping imatinib in patients with Chronic Myeloid Leukaemia.

* To determine the molecular relapse level after more than six month of persistent complete molecular remission without imatinib.

* To determine the complete molecular remission length.

* To evaluate medical and economical impact of stopping imatinib treatment.

Study design : multicentric trial

Study Timeline

• Study First Submitted: 2007-05-23
• Study First Submitted QC: 2007-05-24
• Study First Posted: 2007-05-25
• Study Start: 2007-06
• Primary Completion: 2011-12
• Study Completion: 2011-12
• Status Verified: 2013-07
• Last Update Submitted: 2013-07-01
• Last Update Posted: 2013-07-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients must have reached their 18th birthday
• Women of childbearing potential must agree to use effective methods of contraception
• Patients must be affiliated to a social security regime
• Patients must have received imatinib therapy for at least 36 months.
• Patients must be in complete molecular remission during at least two consecutive years with at least five RT-PCR negative measures for bcr-abl transcripts.
• Patients must be HIV, HCV and HBV negatives
• Patients who have molecular follow-up realized in accordance with international recommendations
• All patients must be informed of the investigational nature of this study and must sign and give written informed consent.

Exclusion Criteria

• Patients who are protected by the law. Patients who are unable to give their consent to participate to the study.
• Patients who have pathologies or treatments that are able to enhance the potential relapse risk after stopping imatinib. Patients who have pathologies or treatments which able to interfere with immunologic study (excepted IFN α):

Corticosteroids or other immuno suppressors Other concomitant malign pathology treated by chemotherapy or radiotherapy Previous or programmed Haematopoietic Stem Cell allogreffe

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	Imatinib ending	Imatinib treatment ending

Primary Outcome Measures

Name	Time	Method
Evaluation of complete molecular remission persistence as measured by RT-PCR negative for bcr-abl transcripts	Every month during the first year and every two months during the second year

Secondary Outcome Measures

Name	Time	Method
T lymphocytes differenciation and proliferation analyse / cytokines production analyse	first visit, M2,M4,M6,M9,M12,M18,M24
T lymphocytes apoptosis analyse	first visit
Haemogramme analyse	every months during two years
Clinical exam	every three months during the first year and every four months during the second year

Trial Locations

Locations (24)

Hôpital Edouard Herriot; 🇫🇷 Lyon, France

Institut Bergonié; 🇫🇷 BORDEAUX Cedex, France

Hôpital André Mignot; 🇫🇷 Le Chesnay Cedex, France

University Hospital Toulouse, Purpan; 🇫🇷 Toulouse, France

University Hospital Bordeaux, Groupe Hospitalier Pellegrin; 🇫🇷 Bordeaux cedex, France

Hôpital Morvan; 🇫🇷 Brest, France

CHU de Grenoble; 🇫🇷 Grenoble, France

Centre hospitalier-service de médecine interne Onco-Hématologique; 🇫🇷 La Roche sur Yon, France

Hôpital Bicêtre, AP-HP; 🇫🇷 Le Kremlin-bicetre, France

Hôpital Claude Huriez; 🇫🇷 Lille, France

Institut Paoli Calmet; 🇫🇷 Marseille Cedex 9, France

Centre Hospitalier de Nevers; 🇫🇷 Nevers, France

CHR de Metz-Thionville; 🇫🇷 Metz Cedex 01, France

Hôpital Necker-Enfants Malades; 🇫🇷 Paris, France

University Hospital Poitiers; 🇫🇷 Poitiers, France

Haut Lévêque Hospital; 🇫🇷 Pessac, France

University Hospital Strasbourg, Hôpital Civil; 🇫🇷 Strasbourg, France

University Hospital Brabois; 🇫🇷 Vandoeuvre Les Nancy, France

Centre Hospitalier Bretagne Atlantique; 🇫🇷 Vannes, France

University Hospital Hôtel-Dieu; 🇫🇷 Nantes, France

Hôpital Henri-Mondor; 🇫🇷 Creteil, Créteil, France

Hôpital Saint Louis; 🇫🇷 PARIS Cedex, Paris, France

University Hospital Angers; 🇫🇷 Angers Cedex 01, Angers, France

University Hospital Nice; 🇫🇷 Nice, France